Cocrystal Pharma, Inc. - Common Stock, par value $0.001 per share (COCP)

CUSIP: 19188J409

Q1 2024 13F Holders as of 31 Mar 2024

Type / Class
Equity / Common Stock, par value $0.001 per share
Shares outstanding
13,831,528
Total 13F shares
721,322
Share change
+38,206
Total reported value
$1,013,555
Price per share
$1.40
Number of holders
14
Value change
+$53,963
Number of buys
5
Number of sells
5

Quarterly Holders Quick Answers

What is CUSIP 19188J409?
CUSIP 19188J409 identifies COCP - Cocrystal Pharma, Inc. - Common Stock, par value $0.001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Top shareholders of COCP - Cocrystal Pharma, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Holder Source Role / Reporting Ownership % Shares Holdings Value 12M Net Δ As of Details
VANGUARD GROUP INC
13F
Company
2%
275,656
$474,735 31 Dec 2023
13F
RENAISSANCE TECHNOLOGIES LLC
13F
Company
0.9%
125,128
$215,000 31 Dec 2023
13F
BlackRock Finance, Inc.
13F
Company
0.54%
74,063
$127,551 31 Dec 2023
13F
GEODE CAPITAL MANAGEMENT, LLC
13F
Company
0.44%
60,432
$102,754 31 Dec 2023
13F
MORGAN STANLEY
13F
Company
0.43%
59,277
$102,087 31 Dec 2023
13F
SUSQUEHANNA INTERNATIONAL GROUP, LLP
13F
Company
0.25%
34,544
$58,725 31 Dec 2023
13F
STATE STREET CORP
13F
Company
0.18%
24,443
$41,553 31 Dec 2023
13F
NORTHERN TRUST CORP
13F
Company
0.09%
12,207
$21,023 31 Dec 2023
13F
BANK OF AMERICA CORP /DE/
13F
Company
0.06%
8,979
$15,462 31 Dec 2023
13F
Tower Research Capital LLC (TRC)
13F
Company
0.04%
5,844
$10,063 31 Dec 2023
13F
JPMORGAN CHASE & CO
13F
Company
0.02%
2,196
$3,733 31 Dec 2023
13F
VIMA LLC
13F
Company
0%
225
$387 31 Dec 2023
13F
UBS Group AG
13F
Company
0%
167
$288 31 Dec 2023
13F
WELLS FARGO & COMPANY/MN
13F
Company
0%
92
$159 31 Dec 2023
13F
NVWM, LLC
13F
Company
0%
84
$145 31 Dec 2023
13F
FMR LLC
13F
Company
0%
4
$7 31 Dec 2023
13F

Institutional Holders of Cocrystal Pharma, Inc. - Common Stock, par value $0.001 per share (COCP) as of Q1 2024

As of 31 Mar 2024, Cocrystal Pharma, Inc. - Common Stock, par value $0.001 per share (COCP) was held by 14 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 721,322 shares. The largest 10 holders included VANGUARD GROUP INC, RENAISSANCE TECHNOLOGIES LLC, BlackRock Inc., GEODE CAPITAL MANAGEMENT, LLC, MORGAN STANLEY, SUSQUEHANNA INTERNATIONAL GROUP, LLP, STATE STREET CORP, UBS Group AG, NORTHERN TRUST CORP, and BANK OF AMERICA CORP /DE/. This page lists 14 institutional shareholders reporting positions in this security for the Q1 2024 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period

Compare Q1 2024 vs Q4 2023 Across Filers

Q4 2023 holders
16
Q1 2024 holders
14
Holder diff
-2
Investor Q4 2023 Shares Q1 2024 Shares Share Diff Share Chg % Q4 2023 Value $ Q1 2024 Value $ Value Diff $ Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .